Show simple item record

dc.contributor.authorBroadley, Simon A
dc.contributor.authorBarnett, Michael H
dc.contributor.authorBoggild, Mike
dc.contributor.authorBrew, Bruce J
dc.contributor.authorButzkueven, Helmut
dc.contributor.authorHeard, Robert
dc.contributor.authorHodgkinson, Suzanne
dc.contributor.authorKermode, Allan G
dc.contributor.authorLechner-Scott, Jeannette
dc.contributor.authorMacdonell, Richard AL
dc.contributor.authorMarriott, Mark
dc.contributor.authorMason, Deborah F
dc.contributor.authorParratt, John
dc.contributor.authorReddel, Stephen W
dc.contributor.authorShaw, Cameron P
dc.contributor.authorSlee, Mark
dc.contributor.authorSpies, Judith
dc.contributor.authorTaylor, Bruce V
dc.contributor.authorCarroll, William M
dc.contributor.authorKilpatrick, Trevor J
dc.contributor.authorKing, John
dc.contributor.authorMcCombe, Pamela A
dc.contributor.authorPollard, John D
dc.contributor.authorWilloughby, Ernest
dc.date.accessioned2018-09-05T01:30:38Z
dc.date.available2018-09-05T01:30:38Z
dc.date.issued2014
dc.identifier.issn0967-5868
dc.identifier.doi10.1016/j.jocn.2014.01.018
dc.identifier.urihttp://hdl.handle.net/10072/68923
dc.description.abstractIn Part 2 of this three part review of multiple sclerosis (MS) treatment with a particular focus on the Australian and New Zealand perspective, we review the newer therapies that have recently become available and emerging therapies that have now completed phase III clinical trial programs. We go on to compare the relative efficacies of these newer and emerging therapies alongside the existing therapies. The effectiveness of ߭interferon in the treatment of different stages and the different disease courses of MS is critically reviewed with the conclusion that the absolute level of response in term of annualised relapse rates (where relapses occur) and MRI activity are similar, but are disappointing in terms of sustained disability progression for progressive forms of the disease. Finally we review the controversial area of combination therapy for MS. Whilst it remains the case that we have no cure or means of preventing MS, we do have a range of effective therapies that when used appropriately and early in the disease course can have a significant impact on short term and longer term outcomes.
dc.description.peerreviewedYes
dc.description.publicationstatusYes
dc.languageEnglish
dc.publisherElsevier
dc.publisher.placeUnited Kingdom
dc.relation.ispartofstudentpublicationN
dc.relation.ispartofpagefrom1847
dc.relation.ispartofpageto1856
dc.relation.ispartofissue11
dc.relation.ispartofjournalJournal of Clinical Neuroscience
dc.relation.ispartofvolume21
dc.rights.retentionY
dc.subject.fieldofresearchMedical and Health Sciences not elsewhere classified
dc.subject.fieldofresearchClinical Sciences
dc.subject.fieldofresearchNeurosciences
dc.subject.fieldofresearchcode119999
dc.subject.fieldofresearchcode1103
dc.subject.fieldofresearchcode1109
dc.titleTherapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 2 New and emerging therapies and their efficacy
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
gro.facultyGriffith Health, School of Medicine
gro.hasfulltextNo Full Text
gro.griffith.authorBroadley, Simon
gro.griffith.authorButzkueven, Helmut


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record